RGA is a high-quality, pure-play life reinsurer compounding book value near 10%, with an 8.7/10 quality score and attractive five-year asymmetric upside.
Reinsurance Group of America, Incorporated (RGA) is a leading global life and health (L&H) reinsurer and a premier provider of capital-relief and customized financial solutions [cite: 1, 2, 3]. Since its incorporation in 1992 as a subsidiary of General American Life Insurance Company and its subsequent initial public offering in 1993, the company has established an extensive global presence across more than 26 countries, maintaining major operations in North America, Europe, the Middle East, Africa (EMEA), and the Asia-Pacific (APAC) region [cite: 2, 4, 5, 6]. With approximately $4.3 trillion of life reinsurance in force and total consolidated assets exceeding $167.1 billion as of June 30, 2026, RGA stands as one of the largest and most technically proficient reinsurance entities in the world [cite: 1, 7]. The firm generates its revenues primarily through net premiums received under long-term reinsurance treaties and net investment income earned on its massive, highly diversified invested asset base [cite: 3, 7, 8, 9].
RGA’s operational segments are divided by geography and business lines, focusing on Traditional Reinsurance and Financial Solutions [cite: 2, 3]. The core products under each of these operational segments are outlined in the table below:
+---------------------------------------------------------------------------------+
| RGA PRODUCT SEGMENTS |
+--------------------------+------------------------------------------------------+
| Segment | Core Products and Risk-Sharing Mechanisms |
+--------------------------+------------------------------------------------------+
| Traditional Reinsurance | Individual and Group Life: Term, whole, universal |
| | health, disability, critical illness, long-term care |
+--------------------------+------------------------------------------------------+
| Financial Solutions | Asset-Intensive: Yield and spread-based reinsurance |
| | Longevity swaps, stable value, capital solutions |
| | Single-premium pension risk transfers (PRT) |
+--------------------------+------------------------------------------------------+
Traditional reinsurance constitutes the foundation of RGA's biological risk-pooling operations [cite: 10]. Through these structures, RGA indemnifies primary insurers against high-severity mortality and morbidity claims [cite: 2, 11]. Financial Solutions, conversely, comprises capital-relief and investment-spread products [cite: 3]. Under these treaties, RGA leverages its balance sheet to assume investment and long-term longevity risks, enabling ceding insurers to optimize regulatory capital requirements and offload legacy liabilities [cite: 2, 3].
The company's primary customer base consists of the largest and most sophisticated primary life and health insurance carriers globally [cite: 3]. In these highly competitive end markets, primary insurers select RGA over multi-line property and casualty (P&C) alternatives due to the firm's specialized biometric modeling expertise, its proprietary automated underwriting platform, AURA, and its customized Strategic Underwriting Programs (SUP) [cite: 4, 6, 12]. Unlike multi-line reinsurers that allocate capital across volatile catastrophe and non-life risks, RGA's pure-play life and health focus allows it to develop deep biometric underwriting partnerships, helping primary carriers accelerate product development and securely manage risk [cite: 4, 6, 13].
RGA's business model is powered by secular demographic trends, institutional capital restructuring, and underwriting innovation [cite: 3, 13, 14]. To evaluate the company’s long-term compounding potential, it is necessary to analyze the underlying drivers of its top-line expansion, its competitive moat, the total addressable market, and its competitive positioning.
RGA's primary revenue generation is driven by premium growth on its massive in-force block, reinvestment yields on its general account portfolio, and the execution of high-margin capital transactions [cite: 3, 4, 7]. Premium growth is sustained by organic "flow" reinsurance treaties (capturing a portion of new policies written by primary carriers) and episodic "in-force block" transactions (reinsuring existing liability portfolios) [cite: 4, 15]. A premier example of the latter is the landmark $32 billion reinsurance transaction completed with Equitable Holdings in 2025, which transferred approximately $18 billion of general account life liabilities to RGA [cite: 13, 16, 17]. This transaction immediately broadened RGA's asset base, generating long-term net investment income and structured spreads [cite: 7, 16].
Strategic growth initiatives are heavily focused on the expansion of Strategic Underwriting Programs (SUP), which utilize RGA's digital infrastructure to co-develop underwriting criteria with primary carriers, creating exclusive reinsurance flow channels [cite: 4, 13]. SUP volumes have doubled year-over-year, establishing a structurally exclusive source of premium income that bypasses traditional competitive bidding processes [cite: 4, 18]. Additionally, RGA continues to scale its Asset-Intensive and Pension Risk Transfer (PRT) businesses [cite: 3, 19]. While the PRT market can fluctuate depending on corporate pension funding levels and market volatility, the structural shift of corporate pension plans transferring defined-benefit liabilities to insurers represents a multi-decade tailwind that RGA selectively bids on across the U.S. and EMEA [cite: 13, 19, 20].
RGA maintains a narrow but highly durable economic moat derived from high switching costs, scale-driven cost advantages, and specialized intellectual property [cite: 1, 2, 12]. Switching costs are immense because reinsurance contracts are long-term, structural treaties designed to run for decades [cite: 2, 12]. Primary carriers face high operational friction, data loss risks, and capital penalties if they attempt to recapture blocks or transfer treaties to other reinsurers [cite: 2].
Scale-driven cost and data advantages are secured by RGA's $4.3 trillion of life insurance in-force [cite: 1, 16]. This massive database provides an unparalleled repository of biometric data, enabling highly precise underwriting and pricing of mortality, morbidity, and longevity risks [cite: 4, 6]. This scale reduces the likelihood of adverse selection and underpricing that smaller competitors face [cite: 4]. Technology integration further strengthens this moat through the AURA automated underwriting system, which processed over 90 million automated underwriting decisions in 2023 [cite: 12]. This platform embeds RGA's proprietary risk rules directly into the point-of-sale software of primary carriers, making it operationally difficult to swap out RGA for alternative reinsurers [cite: 12, 13].
The global reinsurance market represents a massive, compounding addressable opportunity [cite: 12]. The global reinsurance industry was valued at approximately $712.6 billion in 2024 and is projected to scale to $1.53 trillion by 2032, expanding at a compound annual growth rate (CAGR) of 10.14% [cite: 12]. The life reinsurance segment within this TAM accounts for approximately $101.5 billion in annual global premiums [cite: 21]. RGA, Swiss Re, and Great-West Lifeco collectively control 49.5% of this market, highlighting the highly consolidated nature of the industry [cite: 21]. The TAM is further expanded by the massive structural capital needs of primary life insurers [cite: 12, 16]. Due to regulatory transitions, primary insurers are increasingly seeking to offload capital-intensive legacy blocks of life and annuity policies, opening a multi-trillion-dollar addressable pipeline of in-force assets for RGA’s Financial Solutions business [cite: 16, 22, 23].
The competitive landscape is dominated by a few well-capitalized global reinsurers [cite: 12, 21]. RGA's primary competitors include global multi-line giants such as Munich Re, Swiss Re, Hannover Re, SCOR, and Berkshire Hathaway Reinsurance Group [cite: 6, 22, 23]. Unlike these competitors, which are heavily weighted toward Property and Casualty (P&C) catastrophe reinsurance, RGA is uniquely positioned as a pure-play L&H reinsurer [cite: 6]. RGA continues to hold its ground, maintaining its solid number three position globally among non-IFRS-17 reporting reinsurers, with $17.482 billion in Gross Written Premiums, firmly ahead of competitors like Everest Re and RenaissanceRe [cite: 23].
Profitability and operating metric comparisons highlight RGA’s stable positioning relative to its major peers:
+---------------------------------------------------------------------------------+
| GLOBAL REINSURER COMPARATIVE METRICS |
+--------------------------+-----------------------+------------------------------+
| Company Name | GPW / Revenue ($B) | Combined Ratio / ROE % |
+--------------------------+-----------------------+------------------------------+
| Munich Re (IFRS 17) | $35.42 (Gross) | 73.5% Combined Ratio (Group) |
| Swiss Re (IFRS 17) | $34.56 (Gross) | 79.5% Combined Ratio (Group) |
| Hannover Re (IFRS 17) | $31.51 (Gross) | 84.0% Combined Ratio (Group) |
| Berkshire Hathaway (L&H) | $5.00 (L&H Premiums) | N/A |
| RGA (non-IFRS 17) | $17.48 (GPW) | 15.17% Normalized ROE |
+--------------------------+-----------------------+------------------------------+
(Sources: Gross revenues and combined ratios based on reported fiscal results [cite: 6, 22, 23, 24, 25])
While P&C reinsurers are subject to extreme, climate-driven underwriting volatility—evidenced by massive natural catastrophe claims like severe convective storms and hurricanes [cite: 6, 23]—RGA's biometric exposure is highly stable and benefits from natural internal hedging [cite: 6, 10]. Longevity risk acts as a structural hedge against mortality risk; a sudden increase in life expectancy hurts the longevity business but immediately benefits the life insurance portfolio, creating a stable, resilient balance sheet [cite: 6, 26].
RGA's latest financial results demonstrate a highly profitable operating cycle, driven by favorable biometric claims, asset reinvestment tailwinds, and successful execution of key capital initiatives [cite: 4, 7, 15].
Reinsurance Group of America reported its financial results for the second quarter of fiscal year 2026 on August 6, 2026 [cite: 7, 27].
RGA's financial performance during the quarter was highly diversified, with key geographic regions and business lines demonstrating robust operational momentum [cite: 9, 15].
+---------------------------------------------------------------------------------+
| RGA Q2 2026 SEGMENT FINANCIAL PERFORMANCE |
+--------------------------+----------------------+-------------------------------+
| Segment & Business Line | Net Premiums ($M) | Pre-Tax Adj. Op. Income ($M) |
+--------------------------+----------------------+-------------------------------+
| U.S. & LatAm Traditional | $1,961 | $165 |
| U.S. & LatAm Fin. Sol. | Not Provided | $154 |
| Canada Traditional | $348 | $38 |
| Canada Financial Sol. | Not Provided | $18 |
| EMEA Traditional | $568 | $39 |
| EMEA Financial Sol. | Not Provided | $133 |
| APAC Traditional | $850 | $129 |
| APAC Financial Sol. | Not Provided | $120 |
+--------------------------+----------------------+-------------------------------+
(Sources: Segmented premium and operating earnings based on Q2 2026 results [cite: 9, 28])
During the earnings call, management highlighted several key developments:
The market reacted highly favorably to the massive earnings beat, with RGA's share price rising 4.24% on August 7, 2026, to close at $246.33, approaching its all-time high [cite: 15, 29]. Institutional accumulation continued alongside upward analyst revisions [cite: 29, 31]. JPMorgan reiterated its Overweight rating and lifted its 12-month price target to $293 [cite: 31], Barclays raised its target to $290 [cite: 29, 31], and Wells Fargo updated its target to $269 [cite: 27], indicating a consensus expectation of continued fundamental strength. Concurrently, the Board raised the regular quarterly dividend by 5.4% to $0.98 per share [cite: 7, 32].
RGA’s valuation multiples remain highly attractive relative to its compounding earnings profile [cite: 24]. The normalized P/E ratio stands at approximately 8.52x to 10.74x [cite: 24, 30], with a Price-to-Book ratio of 1.15x to 1.17x [cite: 24, 33] and a Price-to-Sales ratio of 0.62x [cite: 24, 34].
Connecting these multiples to the business model reveals that RGA is valued at a discount due to GAAP book value accounting [cite: 24, 35]. Under GAAP, changes in interest rates and credit spreads create unrealized paper losses on the fixed-income portfolio, which are recorded under Accumulated Other Comprehensive Income (AOCI) [cite: 35]. This artificially depresses reported book value during rate hikes, even though these bonds are held to maturity and will not incur realized losses [cite: 36].
When excluding AOCI, RGA's adjusted book value per share stands at $173.77 ($174.11 excluding B36 derivatives) [cite: 7, 28], which has compounded at a 10.1% CAGR since the start of 2021 [cite: 15, 18]. Over the past five years, RGA's annual sales growth has averaged 10.23% [cite: 37]. By combining this consistent double-digit asset and premium growth with a stable ROE of 14% to 17% [cite: 7, 15], the company remains fundamentally undervalued relative to its risk-adjusted capital compounding rate [cite: 38].
Evaluating RGA as a long-term investment requires analyzing various risk dimensions, including execution, competition, regulatory developments, and macroeconomic factors.
The primary execution risk for RGA lies in the underwriting, pricing, and integration of large-scale in-force block transactions, such as the Equitable transaction [cite: 13, 17]. These transactions require assuming billions in long-duration liabilities based on assumptions of mortality, morbidity, and interest rate corridors that span several decades [cite: 2, 3]. If RGA miscalculates the biometric risk profiles of these blocks—for example, if policyholders in a reinsured group experience higher-than-expected mortality or if longevity swaps run significantly longer than modeled—RGA could be forced to strengthen its reserves, which would negatively impact earnings and capital [cite: 2, 3, 19]. Additionally, RGA has increased its per-life retention limit from $8 million to $30 million, which is designed to capture business previously retroceded but exposes the company to higher individual claims volatility [cite: 3].
The global reinsurance market remains highly competitive [cite: 12]. Traditional peers (Munich Re, Swiss Re, and Hannover Re) [cite: 22] and alternative capital providers (private equity-backed reinsurers, captive vehicles, and insurance-linked securities) represent a risk [cite: 12, 39]. Private equity firms have increasingly established capital-light, Bermuda-based reinsurance platforms designed to capture asset-intensive business, presenting a challenge to RGA’s financial solutions segment [cite: 12, 16, 39]. If this alternative capital continues to enter the market aggressively, it could lead to downward pricing pressure, forcing RGA to choose between accepting lower risk-adjusted returns or forfeiting premium volume [cite: 4, 12].
RGA exhibits concentration in its traditional segments, where the five largest primary insurance clients generate a significant portion of gross premiums in select regions [cite: 3]. If a major client decides to increase its "per life" retention limits—such as primary carriers choosing to retain more risk on their balance sheets rather than ceding it to reinsurers—the addressable organic flow premium pool would contract [cite: 2]. Conversely, if a major client faces financial distress, RGA faces counterparty risks, although this is partially mitigated by modified coinsurance structures where assets supporting the reserves are retained by the ceding company [cite: 2].
RGA is subject to a complex, multi-jurisdictional regulatory framework [cite: 3, 40]. The transition to LDTI standards has introduced higher GAAP liability and earnings volatility [cite: 4], and any future changes in statutory accounting formulas could impact statutory capital requirements [cite: 1, 36]. Furthermore, regulators and rating agencies like AM Best are increasingly scrutinizing capital quality and offshore reinsurance structures, particularly the use of Bermuda and Cayman-based reinsurance hubs [cite: 16]. Any regulatory changes that limit the capital relief advantages of these structures could reduce demand for RGA's Capital Solutions [cite: 2, 16, 39].
RGA's balance sheet is heavily exposed to fixed-maturity securities [cite: 41]. While a rising rate environment boosts reinvestment yields, it also subjects the portfolio to mark-to-market bond volatility [cite: 3, 11]. If credit spreads widen dramatically due to a corporate debt crisis, RGA could face credit impairments [cite: 15, 35]. Furthermore, there is capital allocation risk: if management overpays for in-force acquisitions instead of buying back shares or paying down debt, it could dilute the ROE [cite: 15, 42].
A rapid drop in interest rates remains a key macroeconomic risk [cite: 3]. If rates fall back to near-zero levels, RGA's reinvestment yield would drop below its core yield, compressing margins in its asset-intensive business [cite: 3, 4]. Conversely, inflation can drive up administrative costs and health-reinsurance claim costs [cite: 3, 43].
As a life reinsurer, RGA’s ultimate tail risk is a global pandemic or biometric shock that leads to a sustained spike in mortality across multiple age groups [cite: 6]. This was experienced during the COVID-19 pandemic in 2020, which resulted in hundreds of millions in excess mortality claims and compressed earnings [cite: 26].
A structured assessment of RGA's risk landscape helps distinguish between short-term volatility and structural threats:
To model RGA's prospective compounding returns over the next five years (mid-2026 to mid-2031), a detailed scenario analysis is constructed [cite: 44]. This model evaluates potential outcomes based on starting metrics as of August 20, 2026, using two core valuation methodologies: Price-to-Earnings (P/E) and Price-to-Book excluding AOCI (P/B ex-AOCI) [cite: 24, 44].
For each scenario, the Year 5 Book Value per Share (BVPS) and Year 5 Earnings per Share (EPS) are projected as follows [cite: 44]:
$\text{Year 5 BVPS} = \text{Starting BVPS} \times (1 + g_{\text{BVPS}})^5$
$\text{Year 5 EPS} = \text{Starting EPS} \times (1 + g_{\text{EPS}})^5$
The implied price is calculated by taking the average of the P/E-based valuation and the P/B-based valuation [cite: 44]:
$\text{Implied Price} = \frac{(\text{Year 5 EPS} \times \text{Exit P/E}) + (\text{Year 5 BVPS} \times \text{Exit P/B})}{2.0}$
Total Dividends paid over the 5-year period are modeled under the assumption that dividends grow in tandem with EPS [cite: 44]. Total and annualized returns are then computed relative to the starting share price [cite: 44]:
$\text{Total Return} = \frac{\text{Implied Price} + \text{Total Dividends} - \text{Current Price}}{\text{Current Price}}$
$\text{Annualized Return} = \left( \frac{\text{Implied Price} + \text{Total Dividends}}{\text{Current Price}} \right)^{1/5} - 1$
The table below synthesizes the three projected paths for RGA over the 5-year horizon:
+-----------+--------------------+----------------------+--------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| Scenario | Year 5 Revenue / | Year 5 Margin / | Valuation Multiple | Current Share | Implied Future | 5-Year Total | Annualized | Probability |
| | Growth Metric | Earnings Assumption | Assumption | Price (USD) | Share Price (USD) | Return | Return | |
+-----------+--------------------+----------------------+--------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| Low Case | Revenue CAGR: 4.0% | Year 5 EPS: $31.63 | Exit P/E: 7.5x | $249.50 | $229.51 | 0.84% | 0.17% | 20% |
| | BVPS CAGR: 5.0% | Year 5 BVPS: $221.78 | Exit P/B: 1.00x | | | | | |
+-----------+--------------------+----------------------+--------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| Base Case | Revenue CAGR: 8.0% | Year 5 EPS: $39.10 | Exit P/E: 9.5x | $249.50 | $366.17 | 56.86% | 9.42% | 60% |
| | BVPS CAGR: 9.0% | Year 5 BVPS: $267.37 | Exit P/B: 1.35x | | | | | |
+-----------+--------------------+----------------------+--------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| High Case | Revenue CAGR: 12.0%| Year 5 EPS: $46.85 | Exit P/E: 11.5x | $249.50 | $522.05 | 120.58% | 17.14% | 20% |
| | BVPS CAGR: 12.0% | Year 5 BVPS: $306.24 | Exit P/B: 1.65x | | | | | |
+-----------+--------------------+----------------------+--------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
(Source: Projected scenarios and metrics calculated based on structural modeling formulas [cite: 44])
By weighting these three scenario prices by their respective probabilities, the blended 5-year weighted target price is $370.01 USD [cite: 44]. This scenario structure highlights a highly favorable return asymmetry, where the structural downside in a bear market is heavily cushioned by recurring premiums and book value, while the upside under the base and bull scenarios remains highly attractive [cite: 44].
ASYMMETRIC POWER COMPOUNDER
To evaluate RGA's fundamental quality as a long-term compounder, the company is rated on ten core operational and financial metrics, using a standardized 1–10 scale.
The leadership team consists primarily of long-tenured industry insiders, led by CEO Tony Cheng, who took office in January 2024 after a planned transition [cite: 5, 45]. Executive compensation is heavily weighted toward long-term incentives, with 60% to 70% of CEO compensation delivered in performance share units (PSUs) tied to three-year adjusted operating ROE targets [cite: 5]. The CEO is subject to strict stock ownership guidelines equal to five times his base salary [cite: 46]. Collective insider ownership stands at a modest 0.5% to 0.6% of shares outstanding, which is typical for a large-cap financial institution of RGA's scale [cite: 5, 47]. Recent insider activity has shown minor open-market sales, with no insider purchases recorded in the past six months [cite: 27].
RGA exhibits premium revenue quality, driven by long-term treaties that generate highly recurring premium streams [cite: 2, 12]. Since reinsurance treaties are integrated directly into ceding companies' operational frameworks, the recurring premium base is highly predictable [cite: 2, 13]. The volatility associated with Property & Casualty catastrophe reinsurance is absent, and the risk of sudden customer churn is minimized by high structural switching costs [cite: 2, 6].
RGA maintains a dominant position as the premier pure-play global life and health reinsurer [cite: 6]. Along with Swiss Re and Great-West Lifeco, RGA controls a massive 49.5% share of the global L&H reinsurance market [cite: 21]. It consistently ranks as the preferred reinsurer for major global carriers due to its exclusive life focus and digital automated underwriting platform [cite: 6, 12]. The company continues to gain ground in high-value institutional transactions [cite: 13, 16].
The growth outlook remains robust, driven by global demographic aging, which increases demand for mortality and longevity risk-transfer structures [cite: 14]. Furthermore, structural regulatory shifts and interest rate stabilization continue to drive primary carriers to outsource capital-intensive blocks to RGA [cite: 16, 22, 23]. The expansion of Strategic Underwriting Programs (SUP) provides a high-margin premium channel [cite: 4, 13].
The balance sheet is exceptionally strong, characterized by $2.2 billion in excess capital as of Q2 2026, an A+ (Superior) financial strength rating from AM Best, and a total asset base of $167.1 billion [cite: 4, 6, 7]. Debt-to-equity is conservative at approximately 41.4% [cite: 34], and management has optimized its capital structure by paying down $400 million of subordinated debentures [cite: 4].
RGA's business model is highly durable, with a near-zero risk of product obsolescence. The core human need for life and health insurance is structural and long-term [cite: 2]. Operational risk is minimized by RGA's diversified global exposure across multiple regulatory jurisdictions and product lines [cite: 3, 42].
Management executes a disciplined, balanced capital allocation framework [cite: 42]. The company prioritizes high-return organic growth and selective block transactions, such as deploying nearly $500 million into in-force blocks in the first half of 2026 [cite: 4, 15]. Excess capital is returned to shareholders through steady dividend growth and share repurchases [cite: 7, 32].
Wall Street maintains a highly constructive view on RGA, carrying a "Moderate Buy" consensus rating with over 81% of analysts recommending a buy [cite: 30, 48]. Consensus price targets have adjusted upward post-Q2 results to a range of $257.11 to $266.89, with high-end targets reaching $293 to $302 [cite: 30, 34, 48].
Profitability is superior, with RGA consistently generating operating ROEs that exceed its intermediate-term target range of 13% to 15% [cite: 15]. The adjusted operating ROE reached 18.4% as of mid-2026, supported by high underwriting discipline and expanding reinvestment yield spreads [cite: 7, 15].
RGA has a strong history of steady capital growth, compounding its book value per share (excluding AOCI) at an annual rate of 10.1% since the start of 2021 [cite: 15, 18]. Over the past five years, total shareholder return has reached 134.1%, demonstrating a consistent track record of shareholder value creation [cite: 38].
By blending these ten operational and financial metrics, RGA earns a total average quality score of 8.7 out of 10. This high rating reflects RGA's resilient operational structure, strong global market share, clear underwriting discipline, and solid capital position.
EXCEPTIONAL CORPORATE QUALITY
The investment thesis for Reinsurance Group of America (RGA) is anchored on its unique position as a dominant, highly compounding, pure-play global life and health reinsurer [cite: 6]. At a time when property and casualty reinsurers face elevated climate-driven volatility [cite: 6, 23], RGA provides investors with a highly stable, uncorrelated exposure to biometric risk compounding [cite: 6, 10].
Several clear catalysts are expected to drive RGA's equity value upward over the next three to five years:
* The High Interest Rate Tailwind: The persistent mismatch between RGA's legacy portfolio yield of 4.96% and its elevated new money reinvestment rate of 6.02% creates a multi-year investment spread tailwind [cite: 4, 15]. As the company's fixed-income portfolio matures and is reinvested at higher yields, RGA's operating ROE and capital generation are poised to remain elevated [cite: 15].
* Institutional Transaction Capital Acceleration: Demand for capital-optimization solutions among primary life insurers is expanding [cite: 16]. RGA's unique balance sheet scale, coupled with $3.4 billion in deployable capital [cite: 16, 20], positions it as the acquirer of choice for multi-billion-dollar block transfers [cite: 13, 16].
* The Underwriting Technology Advantage: Digital initiatives like AURA and Strategic Underwriting Programs (SUP) are shifting RGA's flow business away from competitive pricing wars and toward high-margin, exclusive partnerships [cite: 4, 12, 13].
The primary investment risk remains a catastrophic biometric tail risk, such as a severe global pandemic [cite: 6, 26]. However, RGA's conservative capitalization, robust retrocession arrangements, and natural longevity hedges provide resilient defensive buffers [cite: 6, 8, 26].
Trading at a modest multiple of approximately 8.5x to 10.7x normalized forward earnings [cite: 24, 30] and 1.15x book value [cite: 24], the stock does not fully reflect RGA's capital compounding rate, high switching costs, and strong global market position [cite: 2, 24]. The underlying fundamentals indicate that RGA remains a high-quality compounder positioned to deliver attractive, risk-adjusted returns [cite: 38, 42].
ATTRACTIVE ASYMMETRIC COUPLING
RGA continues to exhibit robust technical momentum, trading near its all-time high of $251.00 following its blowout Q2 2026 earnings report [cite: 29, 30]. The stock's price action remains in a clear, long-term bullish uptrend, trading well above its major moving averages, with its 50-day moving average standing at $224.17 and its 200-day moving average at $214.35 [cite: 30]. Although the short-term Relative Strength Index (RSI) is approaching overbought levels, indicating potential near-term consolidation [cite: 49], buying pressure remains supported by steady institutional accumulation and positive analyst rating revisions [cite: 29, 31]. The short-term outlook remains highly constructive as the stock consolidates its post-earnings gains, with strong support expected at the $236 to $240 price range [cite: 29, 50].
STRONG BULLISH UPTREND
View Reinsurance Group of America, Incorporated (RGA) stock page
Loading the interactive version of this report…